# Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects

> **NCT04939662** · PHASE2 · COMPLETED · sponsor: **Se-Hoon Lee** · enrollment: 25 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Olaparib+Bevacizumab to SCLC patients

## Key facts

- **NCT ID:** NCT04939662
- **Lead sponsor:** Se-Hoon Lee
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-11
- **Primary completion:** 2023-10-27
- **Final completion:** 2023-10-27
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-01-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04939662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04939662, "Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04939662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*